Completed PHASE1 INTERVENTIONAL NCT00002588

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia

Phase I Trial of Sequential Topotecan(NSC 609699)and Etoposide for Patients With Relapsed, Refractory,or High Risk Acute Myeloid or Lymphoid Leukemia

Sponsor: Case Comprehensive Cancer Center

Conditions Leukemia

Interventions etoposide topotecan hydrochloride

Updated 6 times since 2017 Last updated: Jun 9, 2010 Started: Aug 31, 1994 Primary completion: Jul 31, 2000 Completion: Jan 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002588, this PHASE1 trial focuses on Leukemia and remains completed. Sponsored by Case Comprehensive Cancer Center, it has been updated 6 times since 1994, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States